Ken Griffin Hutchmed (China) LTD Put Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2025 May 15, 2025	BUY	$13.09 - $16.75 $5,236 - $6,700	400 Added 4.35%	9,600 $144,000
Q4 2024 Feb 14, 2025	BUY	$14.25 - $21.35 $115,425 - $172,935	8,100 Added 736.36%	9,200 $132,000
Q3 2024 Nov 14, 2024	SELL	$16.03 - $20.31 $20,839 - $26,403	-1,300 Reduced 54.17%	1,100 $21,000
Q2 2024 Aug 14, 2024	SELL	$16.36 - $21.78 $21,268 - $28,314	-1,300 Reduced 35.14%	2,400 $41,000
Q1 2024 May 15, 2024	BUY	$12.08 - $18.56 $19,328 - $29,695	1,600 Added 76.19%	3,700 $62,000
Q4 2023 Feb 14, 2024	BUY	$16.25 - $20.23 $9,750 - $12,138	600 Added 40.0%	2,100 $38,000
Q3 2023 Nov 14, 2023	SELL	$11.85 - $16.95 $5,925 - $8,475	-500 Reduced 25.0%	1,500 $25,000
Q2 2023 Aug 14, 2023	SELL	$10.78 - $17.73 $28,028 - $46,098	-2,600 Reduced 56.52%	2,000 $24,000
Q1 2023 May 15, 2023	BUY	$13.02 - $19.87 $57,288 - $87,428	4,400 Added 2200.0%	4,600 $59,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $15.51 $1,530 - $3,102	200 New	200 $2,000

6.43M

9.9K

9.6K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.82B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.